@article { ISI:000306642100056,
	title = {Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity},
	journal = {Proceedings of the National Academy of Sciences of the United States of America},
	volume = {109},
	number = {28},
	year = {2012},
	month = {JUL},
	pages = {11294-11299},
	publisher = {NATL ACAD SCIENCES},
	address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
	abstract = {<p>Nanoscale drug delivery vehicles have been harnessed extensively as carriers for cancer chemotherapeutics. However, traditional pharmaceutical approaches for nanoformulation have been a challenge with molecules that exhibit incompatible physicochemical properties, such as platinum-based chemotherapeutics. Here we propose a paradigm based on rational design of active molecules that facilitate supramolecular assembly in the nanoscale dimension. Using cisplatin as a template, we describe the synthesis of a unique platinum (II) tethered to a cholesterol backbone via a unique monocarboxylato and O -\&gt; Pt coordination environment that facilitates nanoparticle assembly with a fixed ratio of phosphatidylcholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine- N-[amino (polyethylene glycol)-2000]. The nanoparticles formed exhibit lower IC50 values compared with carboplatin or cisplatin in vitro, and are active in cisplatin-resistant conditions. Additionally, the nanoparticles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-Ras(LSL/+/)Pten(fl/fl) ovarian cancer models with decreased systemic- and nephro-toxicity. Our results indicate that integrating rational drug design and supramolecular nanochemistry can emerge as a powerful strategy for drug development. Furthermore, given that platinum-based chemotherapeutics form the frontline therapy for a broad range of cancers, the increased efficacy and toxicity profile indicate the constructed nanostructure could translate into a nextgeneration platinum-based agent in the clinics.</p>},
	keywords = {chemotherapy, nanomedicine},
	issn = {0027-8424},
	doi = {10.1073/pnas.1203129109},
	author = {Sengupta, Poulomi and Basu, Sudipta and Soni, Shivani and Pandey, Ambarish and Roy, Bhaskar and Oh, Michael S. and Chin, Kenneth T. and Paraskar, Abhimanyu S. and Sarangi, Sasmit and Connor, Yamicia and Sabbisetti, Venkata S. and Kopparam, Jawahar and Kulkarni, Ashish and Muto, Katherine and Amarasiriwardena, Chitra and Jayawardene, Innocent and Lupoli, Nicola and Dinulescu, Daniela M. and Bonventre, Joseph V. and Mashelkar, Raghunath Anant and Sengupta, Shiladitya}
}
@article { ISI:000373762400005,
	title = {Reporter nanoparticle that monitors its anticancer efficacy in real time},
	journal = {Proceedings of the National Academy of Sciences of the United States of America},
	volume = {113},
	number = {15},
	year = {2016},
	month = {APR},
	pages = {E2104-E2113},
	publisher = {NATL ACAD SCIENCES},
	address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
	abstract = {<p>The ability to monitor the efficacy of an anticancer treatment in real time can have a critical effect on the outcome. Currently, clinical readouts of efficacy rely on indirect or anatomic measurements, which occur over prolonged time scales postchemotherapy or postimmunotherapy and may not be concordant with the actual effect. Here we describe the biology-inspired engineering of a simple 2-in-1 reporter nanoparticle that not only delivers a cytotoxic or an immunotherapy payload to the tumor but also reports back on the efficacy in real time. The reporter nanoparticles are engineered from a novel two-staged stimuli-responsive polymeric material with an optimal ratio of an enzyme-cleavable drug or immunotherapy (effector elements) and a drug function-activatable reporter element. The spatiotemporally constrained delivery of the effector and the reporter elements in a single nanoparticle produces maximum signal enhancement due to the availability of the reporter element in the same cell as the drug, thereby effectively capturing the temporal apoptosis process. Using chemotherapy-sensitive and chemotherapy-resistant tumors in vivo, we show that the reporter nanoparticles can provide a real-time noninvasive readout of tumor response to chemotherapy. The reporter nanoparticle can also monitor the efficacy of immune checkpoint inhibition in melanoma. The self-reporting capability, for the first time to our knowledge, captures an anticancer nanoparticle in action in vivo.</p>},
	keywords = {chemotherapy, immunotherapy, monitoring, nanoparticle, reporter},
	issn = {0027-8424},
	doi = {10.1073/pnas.1603455113},
	author = {Kulkarni, Ashish and Rao, Poornima and Natarajan, Siva and Goldman, Aaron and Sabbisetti, Venkata S. and Khater, Yashika and Korimerla, Navya and Chandrasekar, Vineethkrishna and Mashelkar, Raghunath Anant and Sengupta, Shiladitya}
}
